Skip to main content
. 2019 Jan 25;40:184–197. doi: 10.1016/j.ebiom.2019.01.036

Fig. 5.

Fig. 5

SLC25A11 knockdown reduced NSCLC and melanoma tumor growth in vivo. (a) Volume of subcutaneous tumors derived from SLC25A11 shRNA transduced A549 cells. (b) Representative images of tumors derived from SLC25A11 shRNA transduced A549 cells. (c) Weight of subcutaneous tumors derived from SLC25A11 shRNA transduced A549 cells. (d) Immunohistochemical (IHC) analysis of c-Myc in A549 xenograft tumor tissues and quantification by positive cell counting. (e) Volume of subcutaneous tumors derived from SLC25A11 shRNA transduced A375 cells. (f) Representative images of tumors derived from SLC25A11 shRNA transduced A375 cells. (g) Weight of subcutaneous tumors derived from SLC25A11 shRNA transduced A375 cells. (h) IHC analysis of c-Myc in A375 xenograft tumor tissues and quantification by positive cell counting. (scale bar, 50 μm). (Data were analyzed statistically by two-way analysis of variance ANOVA tests using GraphPad PRISM 5 ***p < .001, **p < .01, *p < .05).